Latest Breaking News On - Natasha drapeau - Page 1 : vimarsana.com

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Patrick alexandreNatasha drapeauSophie baumontOlivier lacombeUs biomedical advanced researchDevelopment of crossjectCohesion bureauDevelopment authorityFrance mayDirector pharmaceutical developmentAdvanced research

Crossject announces publication of clinical data on ZEPIZURE in Neurology and Therapy

Crossject announces publication of clinical data on ZEPIZURE in Neurology and Therapy
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Sophie baumontOlivier lacombeNatasha drapeauPatrick alexandreCohesion bureauDevelopment authorityUs biomedical advanced researchDevelopment of crossjectandFrance mayDirector pharmaceutical developmentAdvanced research

Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe

Extended contract now covers a total of 11 European countries Crossject will receive milestone payments of up to €1 million in total, upon marketing authorizations Crossject will sell.

Natasha drapeauSophie baumontCohesion bureauDevelopment authorityUs biomedical advanced researchFrance mayAdvanced research

Crossject signs a geographic extension of ZEPIZURE commercialization agreement in Europe

Crossject signs a geographic extension of ZEPIZURE commercialization agreement in Europe
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Sophie baumontNatasha drapeauUs biomedical advanced researchCohesion bureauDevelopment authorityFrance mayAdvanced research

Crossject reports audited financial results for 2023

Dijon, France April 25, 2024 Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency.

Natasha drapeauSophie baumontUs biomedical advanced researchDevelopment authorityResearch tax creditCohesion bureauFrance aprilAdvanced researchParis stock exchange alcj